CN Patent

CN110840832A — 一种塞替派注射液及其制备方法

Assigned to Heilongjiang Fuhe Pharmaceutical Group Ltd By Share Ltd · Expires 2020-02-28 · 6y expired

What this patent protects

本发明提供一种塞替派注射液及其制备方法，该塞替派注射液的注射溶剂为二甲基亚砜，每mL二甲基亚砜内含有5‑15mg的塞替派，所述塞替派的含水量低于0.1％；该注射液具有非常好的性状，采用二甲基亚砜为注射溶剂且严格控制塞替派的含水量可以显著提高塞替派注射液的稳定性。

USPTO Abstract

本发明提供一种塞替派注射液及其制备方法，该塞替派注射液的注射溶剂为二甲基亚砜，每mL二甲基亚砜内含有5‑15mg的塞替派，所述塞替派的含水量低于0.1％；该注射液具有非常好的性状，采用二甲基亚砜为注射溶剂且严格控制塞替派的含水量可以显著提高塞替派注射液的稳定性。

Drugs covered by this patent

Patent Metadata

Patent number
CN110840832A
Jurisdiction
CN
Classification
—
Expires
2020-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Heilongjiang Fuhe Pharmaceutical Group Ltd By Share Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.